Obesity has become one of the most serious health challenges in the world today. It affects hundreds of millions of people and increases the risk of many life‑threatening conditions.
People with obesity are more likely to develop heart disease, type 2 diabetes, high blood pressure, fatty liver disease, and certain types of cancer. Obesity can also reduce quality of life, limit mobility, and place heavy emotional and financial burdens on individuals and healthcare systems.
Despite how common obesity is, treatment options remain limited. While lifestyle changes such as healthier eating and regular exercise are often recommended, they are not always enough, especially for people with severe obesity. Surgery can be effective, but it is invasive, expensive, and not suitable for everyone.
At the moment, there are no widely available pills that can safely and effectively treat severe obesity on their own. This has left many people feeling frustrated and without good long‑term solutions.
Now, new research from Johns Hopkins Medicine suggests that help may come from an unexpected place. Scientists have been studying a drug that was originally developed to treat other conditions, including Alzheimer’s disease, schizophrenia, and sickle cell disease. During this research, they discovered that the drug may also help reduce obesity and improve heart health.
The drug works by blocking an enzyme in the body called PDE9. Enzymes are proteins that control chemical reactions inside our cells. PDE9 helps regulate a signaling molecule called cyclic GMP, which plays an important role in how cells respond to stress, manage energy, and control blood flow. When PDE9 is too active, it can interfere with these processes.
The research team, led by Dr. David Kass, has been studying PDE9 for many years. In earlier work published in 2015, they discovered that this enzyme is active in the heart and can make heart disease worse, especially in people with high blood pressure.
That finding led the researchers to ask a bigger question. If blocking PDE9 can protect the heart, could it also improve other health problems linked to obesity?
To explore this idea, the scientists tested a PDE9‑blocking drug in mice. The drug they used is called PF‑04447943. It was originally developed by Pfizer to treat Alzheimer’s disease. Although it did not help with Alzheimer’s, it passed safety testing in clinical trials involving more than 100 people and did not cause serious side effects.
In the mouse study, the results were striking. Mice that received the drug gained less weight and had lower levels of body fat, including fat around the abdomen.
They also showed improvements in fatty liver disease, a condition commonly linked to obesity. In addition, their heart function improved. Most surprising of all, these benefits occurred without any changes to the mice’s diet or physical activity.
The researchers also examined other health markers. They looked at blood pressure, blood sugar levels, cholesterol, and triglycerides. Blocking PDE9 appeared to improve several of these measures, suggesting that the drug may help correct deeper metabolic problems rather than simply suppress appetite.
These findings are especially important given how widespread obesity has become. According to the U.S. Centers for Disease Control and Prevention, more than 40 percent of adults in the United States are obese. Among women over the age of 60, that number rises to about 43 percent. Obesity rates are also increasing in many other countries around the world.
Based on the results seen in mice, the researchers estimate that if similar effects occurred in humans, a person weighing around 250 pounds could potentially lose about 50 pounds using an oral PDE9 inhibitor. This weight loss would occur without strict dieting or increased exercise, which could make treatment far more accessible to many people.
The study, published in the Journal of Clinical Investigation, challenges the idea that obesity is caused only by overeating or lack of willpower. Instead, it supports the growing understanding that obesity is a complex disease involving biology, metabolism, and chemical signaling inside the body.
While these results are promising, the researchers stress that more work is needed. Studies in humans are required to confirm that PDE9 inhibitors are safe and effective for treating obesity and related conditions.
If future trials are successful, this approach could lead to a new kind of obesity treatment that helps millions of people manage their weight and protect their long‑term health.
If you care about diabetes, please read studies about diabetes and vitamin B12, and the right diet for people with type 2 diabetes.
For more health information, please see recent studies about how to eat smart with diabetes, and turmeric and vitamin D: a duo for blood pressure control in diabetic patients.
Copyright © 2026 Knowridge Science Report. All rights reserved.
